Abbott Laboratories (ABT) Research & Development (2009 - 2026)

Abbott Laboratories has reported Research & Development for 18 years, with the latest figure at $892.0 million in Q2 2026.

• Quarterly Research & Development rose 23.03% year-over-year to $892.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.2 billion (up 8.85% YoY) and the FY2025 annual result came in at $2.9 billion, up 3.45% from the prior year.
• Research & Development improved to $892.0 million in Q2 2026 per ABT's latest filing, from $767.0 million in the prior quarter.
• Over five years, Research & Development peaked at $892.0 million in Q2 2026 and troughed at $654.0 million in Q1 2023.
• A 5-year average of $726.3 million and a median of $715.5 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2026: Research & Development fell 14.07% in 2023, then increased 23.03% in 2026.
• Over 5 years, Research & Development stood at $725.0 million in 2022, then slipped by 3.45% to $700.0 million in 2023, then advanced by 7.0% to $749.0 million in 2024, then slipped by 1.87% to $735.0 million in 2025, then gained by 21.36% to $892.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $892.0 million, $767.0 million, and $735.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.